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The Genomics of neonatal 
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Significant variability has been observed in the development and severity of neonatal 
abstinence syndrome (NAS) among neonates exposed to prenatal opioids. Since mater-
nal opioid dose does not appear to correlate directly with neonatal outcome, maternal, 
placental, and fetal genomic variants may play important roles in NAS. Previous studies 
in small cohorts have demonstrated associations of variants in maternal and infant 
genes that encode the μ-opioid receptor (OPRM1), catechol-O-methyltransferase 
(COMT), and prepronociceptin (PNOC) with a shorter length of hospital stay and less 
need for treatment in neonates exposed to opioids in utero. Consistently falling genomic 
sequencing costs and computational approaches to predict variant function will permit 
unbiased discovery of genomic variants and gene pathways associated with differences 
in maternal and fetal opioid pharmacokinetics and pharmacodynamics and with pla-
cental opioid transport and metabolism. Discovery of pathogenic variants should permit 
better delineation of the risk of developing more severe forms of NAS. This review 
provides a summary of the current role of genomic factors in the development of NAS 
and suggests strategies for further genomic discovery.
Keywords: genomics, opioids, neonatal abstinence syndrome, precision medicine, treatment
inTRODUCTiOn
An epidemic of neonatal abstinence syndrome (NAS) currently exists due to dramatic increases 
in prenatal opioid exposure. Significant variability has been noted in the incidence and sever-
ity of NAS among neonates exposed to prenatal opioids. The promise of precision medicine 
has prompted increasing interest in discovery of genomic variants that could better predict the 
development and severity of NAS and suggest new therapeutic approaches for both prevention 
and treatment (1–3). Although the prevalence of NAS has remained stable between 1997 and 
2011 in England and Australia (4), NAS has increased significantly in the United States over 
the past several years from 7 cases/1,000 neonatal intensive care unit admissions in 2004 to 27 
cases/1,000 admissions in 2013 (5). The economic (now >$1.5 billion per year in the United 
States), emotional, and social burdens associated with NAS are substantial due to the frequent 
need for prolonged hospitalizations and the increased risk of adverse long-term neonatal neu-
rodevelopmental outcomes (6, 7). While most neonates developing NAS respond well to treat-
ment with opioids, a subset of exposed infants will require additional pharmacological therapy 
(e.g., phenobarbital, clonidine) and longer hospitalizations (1, 8–10). Multiple environmental fac-
tors such as maternal socioeconomic status and prenatal exposure to other illicit and prescription 
drugs contribute to neonatal outcome. Precision medicine initiatives involving genomic-based 
TAble 1 | Genes associated with NAS phenotype.
Gene SnP Genotype Associated nAS phenotype Annotation CADD 
scorec
Allele frequencies
eA Afr latino
OPRM1 rs1799971 G allelea Less likely to receive treatment; shortened length of stay Missense 
Asn133Asp
24.1 0.13 0.03 0.21
COMT rs4680 G allelea Less likely to receive treatment with two or more medications;  
shortened length of stay
Missense 
Val158Met
11.4 0.48 0.69 0.6
rs4680 G alleleb Less likely to receive treatment with two medications 11.4
rs740603 A allelea Less likely to receive pharmacological treatment; shortened length of stay Intronic 0.2 0.49 0.56 0.61
rs740603 A alleleb Less likely to receive any pharmacological treatment 0.2
PNOC rs351776 A allelea More likely to be treated with two medications; longer length of stay Intronic 1.3 0.44 0.78 0.69
rs351776 A alleleb More likely to receive treatment with two medications; longer length of stay 1.3
rs2614095 A allelea More likely to be treated with two medications Intronic 2.9 0.46 0.11 0.27
rs4732636 A allelea Less likely to receive medication treatment Upstream 6.3 0.28 0.1 0.36
OPRK1 rs702764 C allelea More likely to receive treatment with two medications Synonymous 0.4 0.13 0.49 0.28
OPRD1 rs204076 A alleleb More likely to receive treatment with two medications; longer length of stay Downstream 5.6 0.66 0.83 0.82
DRD2 rs1799732 Deletion Less likely to require treatment with medication Upstream N/A 0.1 0.5 0.12
aInfant allele.
bMaternal allele.
cCombined annotation-dependent depletion (17).
EA, European–American; Afr, African; N/A, not applicable (frame shift).
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prediction of NAS severity are particularly attractive due to 
previous associations between individual genomic variants 
and outcome, poor predictive accuracy of most clinical and 
demographic factors, and rapidly falling sequencing costs 
(2, 11, 12). Epigenetic regulation of genes associated with mater-
nal and fetal drug metabolism and placental drug metabolism 
and transport may also contribute to disease severity and have 
been reviewed previously (13).
ASSOCiATiOnS OF GenOMiC vARiAnTS 
wiTH nAS RiSK AnD SeveRiTY
Based on twin studies, opioid addiction is heritable (14). 
This heritability has prompted case–control studies that have 
examined the association of several single-nucleotide poly-
morphisms (SNPs) in genes known to be involved in opioid 
metabolism and addiction with length of hospitalization, need 
for pharmacologic treatment, and total days of opioid treat-
ment in neonates with NAS (12) (Table 1). Results suggest that 
SNPs in both mother and infant are associated with severity 
of NAS (2, 15–17). For example, in studies of opioid-exposed 
newborn infants and their mothers (2, 15), SNPs in maternal 
and infant genes that encode the μ-opioid receptor (OPRM1), 
catechol-O-methyltransferase (COMT), and prepronociceptin 
(PNOC) were associated with differences in neonatal outcomes 
(length of hospitalization and reduced need for treatment with 
two medications). While the SNPs chosen for study are known 
to have important physiologic roles in opioid drug response 
and withdrawal in adults, the effect sizes of these SNPs have 
been modest and have not had a significant impact on clinical 
practice (2, 16). In addition, differences in allele frequencies 
suggest that the use of a limited number of SNPs as biomarkers 
of disease severity will require race-/ethnicity-based strati-
fication and assessment of admixture (Table  1). Functional 
annotation and prediction programs may permit improved 
risk evaluation of individual SNPs (18) and comparison of the 
contributions of maternal and infant drug metabolism to risk 
of NAS. Finally, the complexity of the genomic architecture, 
developmental regulation of gene expression, and the contribu-
tions of maternal medications and confounding diagnoses will 
require further refinement of SNP-based strategies before they 
can be used clinically.
FUTURe DiReCTiOnS FOR GenOMiCS 
OF nAS ReSeARCH
Extension of current SNP-based studies of the genomics of 
NAS may benefit from leveraging available, diverse large exome 
and genome databases (e.g., http://gnomad.broadinstitute.
org/) to evaluate the predicted function and frequency of both 
common and rare SNPs in genes known to be associated with 
heritable addiction or alterations in drug metabolism. Falling 
sequencing costs will permit complete genomic resolution for 
discovery of clinically actionable genomic variants in indi-
vidual mother/infant dyads. This approach should avoid the 
need to rely on linkage disequilibrium or imputation. Unbiased 
whole exome or genome sequencing would permit the evalu-
ation of the contributions of rare variants in both recognized 
and unrecognized genes to NAS severity. The statistical chal-
lenges associated with rare variant discovery may be partially 
addressed by using family study design (e.g., twin studies) 
to reduce the contributions of highly diverse genomic back-
grounds to phenotype and multiple confounding co-variables 
present in case–control studies. Examining infants with the 
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extremes of NAS severity may also improve statistical power 
to identify relevant genomic variants (19). A review of copy 
number and structural variant databases to identify individuals 
who are haploinsufficient for specific genes might also provide a 
strategy to evaluate functional impact of loss of function alleles 
(20). Standard phenotyping that incorporates predictions of 
functional impact on the metabolism of opioids, as has been 
proposed for the cytochrome P450 genes, along with currently 
accepted measures of NAS severity may also be useful (21, 22). 
Developmental regulation of relevant drug metabolizing and 
placental transport genes will likely require model systems for 
testing gestational age-specific effects of individual variants 
(23, 24). Finally, development of statistical approaches that 
incorporate confounding variables like breastfeeding, smoking, 
and use of protocol-driven medication weaning strategies (25) 
will be important to compare the contributions of genomic 
variants with these kinds of clinical variables. Application of 
precision medicine to the problem of NAS could benefit the 
many adults and neonates exposed to opioids by providing 
individualized risk prediction and leveraging discovery of 
candidate genes for development of novel therapeutic strategies 
(3, 12). For example:
 (A) If we can establish high-risk genetic profiles in young 
women, can we then limit opioid exposure?
 (B) Can we establish low-risk genetic profiles in young women 
and safely wean them off their medication-assisted treat-
ment without an increased risk of relapse?
 (C) If high-risk profiles are found in pregnant women, can we 
intervene and modify risk factors such as limiting cigarette 
smoking and polypharmacy?
 (D) With high-risk profiles identified in neonates, could we 
administer low doses of opioids immediately after birth and 
limit the development and severity of NAS?
 (E) If lower risk profiles are identified in neonates, could we 
send them home earlier and carefully follow them up as an 
outpatient?
 (F) Can pharmacogenomics identify optimal treatment strate-
gies (i.e., best practices) for the mother and her neonate?
 (G) If genetic risk factors can be combined with clinical and 
demographic variables, can we develop “risk assessment” 
models that can be applied to neonates, older children, and 
adults to determine the risk of addiction following exposure 
to opioids (e.g., low, medium, high)?
These are some of the potential benefits of a more preci-
sion medicine-guided approach that could be adopted with 
rapid development of novel genomics methodologies. What is 
most important is sufficient funding, and legislative efforts are 
currently driving this innovation and offer a path forward to 
address NAS in this highly vulnerable population.
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